HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ilgin, N. Articles by Frost, J. J. Search for Related Content PubMed PubMed Citation Articles by Ilgin, N. Articles by Frost, J. J.

PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson’s disease

From the Department of Radiology (Drs. Ilgin, Dannals, Ravert, and Frost), Division of Nuclear Medicine, and Departments of Neurology (Dr. Reich) and Neuroscience (Dr. Frost), Johns Hopkins Medical Institutions, Baltimore, MD; and The Johns Hopkins University School of Medicine (Dr. Zubieta), Department of Radiology, Division of Nuclear Medicine, Baltimore, MD.

Address correspondence and reprint requests to Dr. J. James Frost, The Johns Hopkins University School of Medicine, Department of Radiology, Nelson Building B1-130, 600 N. Wolfe Street, Baltimore, MD 21287.

OBJECTIVE: To differentiate the patterns of dopamine transporter loss between idiopathic PD and progressive supranuclear palsy (PSP).

METHODS: We used the radiotracer [¹¹C]-WIN 35,428 and PET. Regional striatal dopamine transporter binding was measured in the caudate, anterior putamen, and posterior putamen of six patients with L-dopa–responsive stage 2 PD, six patients with PSP, and six age-comparable healthy controls.

RESULTS: In patients with idiopathic PD, the most marked abnormality was observed in the posterior putamen (77% reduction), whereas transporter density in the anterior putamen (60% reduction) and the caudate (44% reduction) was less affected. Unlike the patients with PD, the PSP group showed a relatively uniform degree of involvement in the caudate (40% reduction), anterior putamen (47% reduction), and posterior putamen (51% reduction). When posterior putamen/caudate ratios were calculated, these values were significantly lower in patients with PD than they were in patients with PSP (p = 0.0008) and the control group (p < 0.0001).

CONCLUSIONS: Patients with PD have a more pronounced loss of dopamine transporters in the posterior putamen due to a subdivisional involvement of nigrostriatal dopaminergic projections in idiopathic PD. This technique is useful in the determination of neurochemical changes underlying PD and PSP, thus differentiating between them.

This article has been cited by other articles:

				S. Chalon, H. Hall, W. Saba, L. Garreau, F. Dolle, C. Halldin, P. Emond, M. Bottlaender, J.-B. Deloye, J. Helfenbein, et al. Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 147 - 152. [Abstract] [Full Text] [PDF]

				M. Suzuki, T. J. Desmond, R. L. Albin, and K. A. Frey Cholinergic vesicular transporters in progressive supranuclear palsy Neurology, April 9, 2002; 58(7): 1013 - 1018. [Abstract] [Full Text] [PDF]

				P. Piccini, J. de Yebenez, A. J. Lees, R. Ceravolo, N. Turjanski, P. Pramstaller, and D. J. Brooks Familial Progressive Supranuclear Palsy: Detection of Subclinical Cases Using 18F-Dopa and 18Fluorodeoxyglucose Positron Emission Tomography Arch Neurol, November 1, 2001; 58(11): 1846 - 1851. [Abstract] [Full Text] [PDF]

				K. B. Baker and E. B. Montgomery Jr. Performance on the PD test battery by relatives of patients with progressive supranuclear palsy Neurology, January 9, 2001; 56(1): 25 - 30. [Abstract] [Full Text] [PDF]